NCT06866548View on ClinicalTrials.gov

Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2028

Conditions
mCRPC
Interventions
DRUG

anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb (Tislelizumab)

"Drug: Teprotumumab/IBI311 Given by IV infusion Initiate dosing with 10 mg/kg for first infusion, followed by 20 mg/kg every 3 weeks.~Drug: Tislelizumab Given by IV infusion 200 mg every 3 weeks"

Trial Locations (1)

Unknown

RECRUITING

Shanghai Changzheng Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Changzheng Hospital

OTHER